<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862613</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.513</article-id><article-id pub-id-type="other">EPP0340</article-id><article-id pub-id-type="pii">S0924933824005133</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Association between metabolic syndrome, cognitive dysfunctions, and peripheral inflammation in schizophrenia</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kancsev</surname><given-names>A.</given-names></name><xref rid="aff1146" ref-type="aff">
<sup>1</sup></xref><xref rid="cor0374" ref-type="corresp">
<sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kelemen</surname><given-names>O.</given-names></name><xref rid="aff1147" ref-type="aff">
<sup>2</sup></xref><xref rid="aff1148" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>K&#x000e9;ri</surname><given-names>S.</given-names></name><xref rid="aff1149" ref-type="aff">
<sup>4</sup></xref><xref rid="aff1150" ref-type="aff">
<sup>5</sup></xref><xref rid="aff1151" ref-type="aff">
<sup>6</sup></xref></contrib></contrib-group><aff id="aff1146">
<sup>1</sup>Department of Psychiatry and Psychotherapy, <institution>SZSZBMK J&#x000f3;sa Andr&#x000e1;s University Teaching Hospital</institution>, <city>Ny&#x000ed;regyh&#x000e1;za</city>
</aff><aff id="aff1147">
<sup>2</sup>Department of Behavioral Sciences, Albert Szent-Gy&#x000f6;rgyi Medical School, <institution>University of Szeged</institution>, <city>Szeged</city>
</aff><aff id="aff1148">
<sup>3</sup>Department of Psychiatry, <institution>B&#x000e1;cs-Kiskun County Hospital</institution>, <city>Kecskem&#x000e9;t</city>
</aff><aff id="aff1149">
<sup>4</sup>Department of Cognitive Science, <institution>Budapest University of Technology and Economics</institution>
</aff><aff id="aff1150">
<sup>5</sup><institution>National Institute of Mental Health, Neurology, and Neurosurgery</institution>, <city>Budapest</city>
</aff><aff id="aff1151">
<sup>6</sup>Department of Physiology, Albert Szent-Gy&#x000f6;rgyi Medical School, <institution>University of Szeged</institution>, <city>Szeged</city>, <country>Hungary</country>
</aff><author-notes><corresp id="cor0374">
<label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="488">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S241</fpage><lpage>S242</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824005133a.pdf"/><abstract><sec id="sec2245"><title>Introduction</title><p>Metabolic syndrome (MetS) is of primary clinical interest because of its harmful impact on the general health and quality of life of patients with psychotic disorders. Paradoxically, MetS is associated with impaired cognitive functions in patients receiving antipsychotics primarily shown to improve cognition (e.g., clozapine and olanzapine).</p></sec><sec id="sec2246"><title>Objectives</title><p>
In this study, we aimed to investigate the relationship between MetS, cognitive functions, and peripheral inflammation.</p></sec><sec id="sec2247"><title>Methods</title><p>The participants were 154 patients with schizophrenia. Fifty-seven patients met the criteria of MetS. We evaluated cognitive functions with the Repeated Battery for the Assessment of Neuropsychological Status (RBANS). The Positive and Negative Syndrome Scale (PANSS) quantified the clinical symptoms. We also measured the plasma levels of IL-6 and C-reactive protein (CRP). In addition to conventional statistics, we also calculated Cohen&#x02019;s effect size (d) and Bayes Factors (BF10).</p></sec><sec id="sec2248"><title>Results</title><p>Results revealed that patients with MetS exhibited worse cognitive function relative to patients without Mets in attention (d = 0.19, BF10 = 2.3) and delayed memory (d = 0.25, BF10 = 5.7). No significant between-group differences existed in immediate memory, visuospatial functions, and language. The MetS and non-MetS groups did not differ in positive, negative, or general symptoms. Higher IL-6 levels were associated with worse delayed memory (r=-0.56, BF10=34.6).</p></sec><sec id="sec2249"><title>Conclusions</title><p>Our results suggest that MetS-associated cognitive dysfunctions are less severe than reported in the literature: it was confined to two cognitive domains, the effect size was small, and the Bayesian evidence level was weak. Peripheral inflammation may mediate the association between MetS and long-term memory dysfunctions.</p></sec><sec id="sec2250"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>